Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
@article{211034,
author = {Shubham Yadav and Vivek Kumar Patel},
title = {The Wrong Kind of Success: EGCG Solid Lipid Nanoparticles and the 800 mg Ceiling},
journal = {International Journal of Innovative Research in Technology},
year = {2026},
volume = {13},
number = {6},
pages = {3322-3333},
issn = {2349-6002},
url = {https://ijirt.org/article?manuscript=211034},
abstract = {Epigallocatechin-3-gallate is lost three times over before it reaches the circulation. It is chemically destroyed in the intestinal lumen, where simulated gastric and small intestinal digestion removes 71 to 91% of it against 7 to 11% for catechin and epicatechin, and where it autoxidises to theasinensin dimers; in sodium phosphate buffer at pH 7.4 roughly 90% is gone within three hours. What survives crosses the epithelium poorly, being a hydrophilic molecule of 458 Da with eight hydrogen-bond donors. What crosses is then conjugated, appearing in mouse plasma 50 to 90% as the glucuronide. The human result is that plasma concentrations exceed 1 µM only above a one-gram oral dose. Solid lipid nanoparticles address the first of these losses directly and the second indirectly, and reported systems reach 108 to 122 nm with entrapment efficiencies from 68.5% to above 93%. This review argues that the interesting problem lies beyond that. First, there is a mismatch that most reports pass over: a hydrophilic molecule is being asked to partition into a lipid matrix, which is why entrapment values scatter so widely and why burst release and expulsion on storage are the characteristic failures. Second, and more consequentially, EGCG has a defined and regulated hepatic ceiling. The European Food Safety Authority concluded in 2018 that supplemental doses at or above 800 mg EGCG per day produce a statistically significant rise in serum transaminases, and the European Union amended its fortification regulation accordingly. That limit is written as a dose in milligrams, not as a plasma exposure, so a carrier that triples bioavailability delivers the systemic exposure of 800 mg from a label-compliant 270 mg. For a compound whose dose-limiting toxicity is hepatic, improving absorption narrows the therapeutic window rather than widening it, and that is a result a formulation study can and should measure rather than inherit.},
keywords = {Epigallocatechin-3-gallate; solid lipid nanoparticles; oral bioavailability; chemical stability; autoxidation; theasinensin; hepatotoxicity; Quality by Design},
month = {November},
}
Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.
Join NowNational Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024
Submit inquiry